路透社11月18日 - 美国食品药品监督管理局(FDA)周三批准了 赛诺菲的 SASY.PA 口服药物文格卢斯塔特(venglustat),该监管机构表示, 这使其成为首款用于治疗一种影响大脑和神经系统的罕见遗传性疾病的 药物。
路透社11月18日 - 美国食品药品监督管理局(FDA)周三批准了 赛诺菲的 SASY.PA 口服药物文格卢斯塔特(venglustat),该监管机构表示, 这使其成为首款用于治疗一种影响大脑和神经系统的罕见遗传性疾病的 药物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.